180 related articles for article (PubMed ID: 12788413)
1. Does amifostine have a role in chemoradiation treatment?
Brizel DM; Overgaard J
Lancet Oncol; 2003 Jun; 4(6):378-81. PubMed ID: 12788413
[TBL] [Abstract][Full Text] [Related]
2. The role of amifostine as a radioprotector.
Wasserman TH; Brizel DM
Oncology (Williston Park); 2001 Oct; 15(10):1349-54; discussion 1357-60. PubMed ID: 11702962
[TBL] [Abstract][Full Text] [Related]
3. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
Braaksma M; Levendag P
Semin Oncol; 2002 Dec; 29(6 Suppl 19):63-70. PubMed ID: 12577248
[TBL] [Abstract][Full Text] [Related]
4. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Brizel DM; Wasserman TH; Henke M; Strnad V; Rudat V; Monnier A; Eschwege F; Zhang J; Russell L; Oster W; Sauer R
J Clin Oncol; 2000 Oct; 18(19):3339-45. PubMed ID: 11013273
[TBL] [Abstract][Full Text] [Related]
5. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences.
Capizzi RL; Oster W
Eur J Cancer; 1995; 31A Suppl 1():S8-13. PubMed ID: 7577096
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
Anné PR
Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
[TBL] [Abstract][Full Text] [Related]
7. Cytoprotection/radioprotection with amifostine: potential role in cervical cancer and early findings in the Radiation Therapy Oncology Group C-0116 trial.
Small W;
Semin Oncol; 2003 Dec; 30(6 Suppl 18):68-71. PubMed ID: 14727243
[TBL] [Abstract][Full Text] [Related]
8. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma.
Bourhis J; Rosine D
Semin Oncol; 2002 Dec; 29(6 Suppl 19):61-2. PubMed ID: 12577247
[TBL] [Abstract][Full Text] [Related]
9. Costs of treatment intensification for head and neck cancer: concomitant chemoradiation randomised for radioprotection with amifostine.
Braaksma M; van Agthoven M; Nijdam W; Uyl-de Groot C; Levendag P
Eur J Cancer; 2005 Sep; 41(14):2102-11. PubMed ID: 16140526
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer.
Antonadou D; Pepelassi M; Synodinou M; Puglisi M; Throuvalas N
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):739-47. PubMed ID: 11849797
[TBL] [Abstract][Full Text] [Related]
11. Amifostine and radiation therapy: past, present, and future.
Tannehill SP; Mehta MP
Semin Oncol; 1996 Aug; 23(4 Suppl 8):69-77. PubMed ID: 8783671
[TBL] [Abstract][Full Text] [Related]
12. Randomized double-blind trial of amifostine versus placebo for radiation-induced xerostomia in patients with head and neck cancer.
Lee MG; Freeman AR; Roos DE; Milner AD; Borg MF
J Med Imaging Radiat Oncol; 2019 Feb; 63(1):142-150. PubMed ID: 30461207
[TBL] [Abstract][Full Text] [Related]
13. [Current status and perspectives of using radioprotectors in clinical practice].
Bondaruk OS; Moskalets' OI
Lik Sprava; 2003; (7):3-12. PubMed ID: 14723126
[TBL] [Abstract][Full Text] [Related]
14. Exploring the role of the radioprotector amifostine in locally advanced non-small cell lung cancer: Radiation Therapy Oncology Group trial 98-01.
Movsas B
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):40-5. PubMed ID: 11917283
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of amifostine on dental health after radiotherapy of the head and neck.
Rudat V; Meyer J; Momm F; Bendel M; Henke M; Strnad V; Grötz K; Schulte A
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1339-43. PubMed ID: 11121631
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic normal tissue protection in clinical radiation oncology: focus on amifostine.
Mell LK; Movsas B
Expert Opin Drug Metab Toxicol; 2008 Oct; 4(10):1341-50. PubMed ID: 18798703
[TBL] [Abstract][Full Text] [Related]
17. Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data.
Bourhis J; Blanchard P; Maillard E; Brizel DM; Movsas B; Buentzel J; Langendijk JA; Komaki R; Swan Leong S; Levendag P; Pignon JP
J Clin Oncol; 2011 Jun; 29(18):2590-7. PubMed ID: 21576630
[TBL] [Abstract][Full Text] [Related]
18. A new administration schedule for amifostine as a radioprotector in cancer therapy.
Wagner W; Radmard A; Schönekaes KG
Anticancer Res; 1999; 19(3B):2281-3. PubMed ID: 10472344
[TBL] [Abstract][Full Text] [Related]
19. Proceedings of the Fourth International Cytoprotection Investigators' Congress. May 2004. Philadelphia, Pennsylvania, USA.
Semin Oncol; 2004 Dec; 31(6 Suppl 18):1-73. PubMed ID: 15801121
[No Abstract] [Full Text] [Related]
20. The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy.
Marcu LG
Eur J Cancer Care (Engl); 2009 Mar; 18(2):116-23. PubMed ID: 19267726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
